• Genetic Signatures receives $4.4m refund from Australian Taxation Office under R&D tax incentive program
• Refund covers eligible Australian and international R&D activities during FY2025
• Funds will support further development and commercialization of the company's proprietary 3base® molecular diagnostics platform

Genetic Signatures Limited, a global molecular diagnostics company, has announced that it has received a refund of $4,382,365 from the Australian Taxation Office under the Research and Development (R&D) tax incentive program. The R&D tax incentive is an Australian Government program that provides cash refunds to companies for eligible Australian and international R&D activities conducted during the financial year. The funds received will support Genetic Signatures' ongoing development and commercialization of its proprietary 3base® molecular diagnostics platform. The 3base® platform enables high-volume hospital and pathology laboratories to rapidly and cost-effectively screen for a wide array of infectious pathogens, including COVID-19, gastroenteritis, antibiotic-resistant bacteria, sexually transmitted infections, meningitis, and mosquito-borne viral diseases. Genetic Signatures continues to leverage strong sales of its EasyScreen™ respiratory kits and growing interest in its gastroenteritis products to further expand the reach of its 3base® technology globally.